HIV Infection Clinical Trial
Official title:
Gene Therapy for AIDS Using Retroviral Mediated Gene Transfer to Deliver HIV-1 Anti-Sense TAR and Transdominant Rev Protein Genes to Syngeneic Lymphocytes in HIV-1 Infected Identical Twins
This study will test the safety and effectiveness of genetically altered T lymphocytes
(white blood cells of the immune system) in reducing viral load in patients infected with
the human immunodeficiency virus (HIV). The lymphocytes will have two genes inserted into
them; a laboratory-manufactured anti-HIV gene designed to inhibit HIV reproduction (either
the RevTD or Rev-TD-antiTAR gene), and a "marker" gene that will show whether or not the
inserted genes have gotten into the cells.
Identical twin pairs 18 years of age and older- one of whom is HIV-positive (infected with
the human immunodeficiency virus) and the other HIV-negative (not infected) may be eligible
for this study.
All participants will have a complete medical history and physical examination, blood tests
and a tetanus booster shot, if indicated. The non HIV-infected twin will then undergo
lymphapheresis to collect lymphocytes. In this procedure, whole blood is collected through a
needle placed in an arm vein. The blood circulates through a machine that separates it into
its components. The lymphocytes are then removed, and the red cells and plasma are returned
to the donor, either through the same needle or through a second needle placed in the other
arm.
The donor cells are grown in the laboratory for a few days, and then the new genes are
inserted into them. The genetically altered cells are grown in the laboratory for several
days until their numbers increase approximately a thousand-fold. They are then infused
intravenously (through a vein) into the infected twin. These procedures-lymphapheresis, gene
modification and infusion-will be repeated at approximately 2-month intervals up to four
times.
Each lymphocyte infusion takes about 60 minutes. The patient's vital signs (temperature,
pulse, blood pressure and breathing) are monitored frequently during the infusion and hourly
for 4 hours after the infusion. Blood samples are taken the day of the infusion, 3 days
later, and then weekly to monitor the gene-modified cells, immune status, viral activity,
and other factors. These tests may be done less often as the study progresses and more is
learned about the safety of the infusions. The infusions are done on an outpatient basis
unless side effects require that they be done in the hospital with post-infusion monitoring
for at least 24 hours.
Patients will be followed for long-term effects of treatment monthly for the first 3 months,
once a month for the next 9 months and yearly from then on.
This study will contribute information about the use and side effects of gene therapy in HIV
infection that may lead to new treatment strategies. A potential direct benefit to
HIV-infected individuals participating in this study is reduced viral load; in laboratory
studies, the RevTD and Rev-TD-antiTAR genes have inhibited HIV spread in the test tube.
However, this is an early phase of study, and the likelihood of receiving this benefit is
unknown.
Status | Completed |
Enrollment | 48 |
Est. completion date | March 2002 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
INCLUSION CRITERIA: - An identical twin pair, one of whom is seropositive for HIV-1, the other twin seronegative, by standard ELISA and Western blot testing. - Patients with Kaposi's sarcoma limited to the skin and/or mucous membranes are eligible for this study, but must not have received any systemic therapy for - KS within 4 weeks prior to entry. The diagnosis of KS must have been confirmed by biopsy. - Free from serious psychological or emotional illness and able to provide written informed consent. - Anticipated survival greater than 3 months. - 18 years of age or older. - Treatment with FDA-approved and/or expanded access antiretroviral agent(s) for patients with baseline CD4 counts below 500 cells/mm(3). Patients with baseline CD4 counts above 500 cells/mm(3) are eligible to receive cell therapy on this protocol, but must be treated with antiretroviral therapy if evidence of significant and persistent viral activation occurs in association with a cell infusion. "Significant and persistent viral activation" is defined as a 50 percent or greater increase above baseline in any virologic parameter for at least 2 consecutive weeks. - Recipient's CD4 count greater than 50 cells/mm(3). - Recipient and Donor willing to have samples stored and undergo HLA testing. EXCLUSION CRITERIA (Donor and Recipient): - Lymphomas. - Unwillingness to comply with current NIH Clinical Center guidelines concerning appropriate notification of all current sexual partners of an individual regarding his or her HIV-1 positive sero-status and the risk of transmission of HIV-1 infection. - Recent history of substance abuse unless evidence is provided of an ongoing therapeutic intervention (i.e. medical therapy or counseling) to control such abuse. - Pregnant at entry or unwillingness to practice barrier birth control or abstinence during the study. - No experimental therapy within 4 weeks of study participation. Antiretroviral agents available on an FDA-sanctioned, expanded access basis are permitted. EXCLUSION CRITERIA (Donor): - Untreated or inadequately treated medical condition (e.g., cardiopulmonary disease, acute infection) which, in the judgement of the Principal Investigator, precludes apheresis. - Serologic positivity for Epstein Barr virus, Cytomegalovirus, Hepatitis B or Hepatitis C, if and only if the recipient twin tests seronegative for the corresponding virus. |
Endpoint Classification: Safety Study, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | National Human Genome Research Institute (NHGRI) | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Human Genome Research Institute (NHGRI) |
United States,
Lane HC, Zunich KM, Wilson W, Cefali F, Easter M, Kovacs JA, Masur H, Leitman SF, Klein HG, Steis RG, et al. Syngeneic bone marrow transplantation and adoptive transfer of peripheral blood lymphocytes combined with zidovudine in human immunodeficiency virus (HIV) infection. Ann Intern Med. 1990 Oct 1;113(7):512-9. — View Citation
Morgan RA, Walker R. Gene therapy for AIDS using retroviral mediated gene transfer to deliver HIV-1 antisense TAR and transdominant Rev protein genes to syngeneic lymphocytes in HIV-1 infected identical twins. Hum Gene Ther. 1996 Jun 20;7(10):1281-306. — View Citation
VandenDriessche T, Chuah MK, Chiang L, Chang HK, Ensoli B, Morgan RA. Inhibition of clinical human immunodeficiency virus (HIV) type 1 isolates in primary CD4+ T lymphocytes by retroviral vectors expressing anti-HIV genes. J Virol. 1995 Jul;69(7):4045-52. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02135419 -
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
|
Phase 3 | |
Active, not recruiting |
NCT02663856 -
My Smart Age With HIV: Smartphone Self-assessment of Frailty
|
||
Completed |
NCT02663869 -
Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles
|
||
Completed |
NCT02921516 -
Growing Up: Intervening With HIV-Positive Adolescents in Resource-Poor Settings
|
N/A | |
Completed |
NCT02846402 -
Impact of HIV Self-testing Among Female Sex Workers in Kampala, Uganda
|
N/A | |
Terminated |
NCT02743598 -
Liraglutide for HIV-associated Neurocognitive Disorder
|
Phase 4 | |
Completed |
NCT02659306 -
Metformin Immunotherapy in HIV Infection
|
Phase 1 | |
Completed |
NCT02564341 -
Targeting Effective Analgesia in Clinics for HIV - Intervention
|
N/A | |
Active, not recruiting |
NCT02302950 -
A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas
|
N/A | |
Completed |
NCT01852942 -
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
|
Phase 2 | |
Completed |
NCT01830595 -
Lactoferrin Treatment in HIV Patients
|
Phase 2 | |
Completed |
NCT02269605 -
Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment
|
Phase 1 | |
Terminated |
NCT01902186 -
Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir
|
Phase 4 | |
Terminated |
NCT02109224 -
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
|
Phase 1 | |
Completed |
NCT02527135 -
Text Messaging to Improve HIV Testing Among Young Women in Kenya
|
N/A | |
Completed |
NCT01946217 -
Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials
|
N/A | |
Completed |
NCT02525146 -
Birmingham Access to Care Study
|
N/A | |
Completed |
NCT02118168 -
Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002
|
N/A | |
Active, not recruiting |
NCT02602418 -
Neural Correlates of Working Memory Training for HIV Patients
|
N/A | |
Completed |
NCT01702974 -
Immune Reconstitution in HIV Disease (IREHIV)
|
Phase 2 |